Design of a Potent CB1Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents
Citations Over TimeTop 10% of 2012 papers
Abstract
Antagonism of cannabinoid-1 (CB1) receptor signaling has been demonstrated to inhibit feeding behaviors in humans, but CB1-mediated central nervous system (CNS) side effects have halted the marketing and further development of the lead drugs against this target. However, peripherally restricted CB1 receptor antagonists may hold potential for providing the desired efficacy with reduced CNS side effect profiles. In this report we detail the discovery and structure-activity-relationship analysis of a novel bicyclic scaffold (3) that exhibits potent CB1 receptor antagonism and oral activity in preclinical feeding models. Optimization of physical properties has led to the identification of analogues which are predicted to have reduced CNS exposure and could serve as a starting point for the design of peripherally targeted CB1 receptor antagonists.
Related Papers
- → CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents(2004)241 cited
- → Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes(2002)101 cited
- → Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles(1992)141 cited
- → Cannabinoid–improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor(2006)9 cited
- → Cannabinoid Ligand-Receptor Signaling During Early Pregnancy in the Mouse(1999)3 cited